ATE224712T1 - Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen - Google Patents

Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen

Info

Publication number
ATE224712T1
ATE224712T1 AT94916710T AT94916710T ATE224712T1 AT E224712 T1 ATE224712 T1 AT E224712T1 AT 94916710 T AT94916710 T AT 94916710T AT 94916710 T AT94916710 T AT 94916710T AT E224712 T1 ATE224712 T1 AT E224712T1
Authority
AT
Austria
Prior art keywords
fibrotic
injuries
repairing
compositions
methods
Prior art date
Application number
AT94916710T
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE224712T1 publication Critical patent/ATE224712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
AT94916710T 1993-05-07 1994-05-09 Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen ATE224712T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5921493A 1993-05-07 1993-05-07
US6483193A 1993-05-19 1993-05-19
PCT/US1994/005156 WO1994026249A1 (en) 1993-05-07 1994-05-09 Compositions and methods for reparation and prevention of fibrotic lesions

Publications (1)

Publication Number Publication Date
ATE224712T1 true ATE224712T1 (de) 2002-10-15

Family

ID=26738503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916710T ATE224712T1 (de) 1993-05-07 1994-05-09 Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen

Country Status (10)

Country Link
EP (1) EP0702551B1 (de)
JP (1) JPH08510251A (de)
AT (1) ATE224712T1 (de)
AU (1) AU687816B2 (de)
BR (1) BR9406461A (de)
CA (1) CA2161648A1 (de)
DE (1) DE69431433T2 (de)
ES (1) ES2183839T3 (de)
NO (1) NO308507B1 (de)
WO (1) WO1994026249A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
AU697742B2 (en) * 1995-03-03 1998-10-15 Intermune, Inc. Treatment of cytokine growth factor caused disorders
AU698619B2 (en) * 1995-06-07 1998-11-05 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors
JP2002522462A (ja) * 1998-08-13 2002-07-23 ハダシット・メディカル・リサーチ・サービシイズ・アンド・ディベロプメント・カンパニー・リミテッド 組織外傷に関連した病原プロセスの阻害
US6492395B1 (en) 1998-09-18 2002-12-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
EP1356816B1 (de) * 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2004073680A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. 液滴分散型軟膏剤
WO2004089283A2 (en) * 2003-04-04 2004-10-21 Intermune, Inc. Compositions and methods for treating viral infections
WO2005047256A1 (en) 2003-11-14 2005-05-26 Shanghai Genomics, Inc. The derivatives of pyridone and the use of them
JP2008544743A (ja) 2005-05-10 2008-12-11 インターミューン インコーポレイテッド ストレス活性化蛋白質キナーゼ系をモジュレートするためのピリドン誘導体
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
PT2029572E (pt) * 2006-06-05 2011-02-09 Novartis Ag Compostos orgânicos
JP5213852B2 (ja) 2006-06-15 2013-06-19 シャンハイ ゲノミックス インク 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
EP2219650B1 (de) 2007-10-26 2014-05-07 Pacific Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von fibroproliferativen erkrankungen
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
DK2670242T3 (da) * 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
JP5872564B2 (ja) * 2011-09-14 2016-03-01 塩野義製薬株式会社 吸入用医薬組成物
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP4491180A1 (de) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol-pirfenidon- und pyridonanalogverbindungen und verwendungen davon
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions

Also Published As

Publication number Publication date
BR9406461A (pt) 1996-01-30
NO954437D0 (no) 1995-11-06
AU6829194A (en) 1994-12-12
CA2161648A1 (en) 1994-11-24
DE69431433D1 (de) 2002-10-31
EP0702551A4 (de) 1997-08-20
JPH08510251A (ja) 1996-10-29
AU687816B2 (en) 1998-03-05
EP0702551A1 (de) 1996-03-27
NO308507B1 (no) 2000-09-25
ES2183839T3 (es) 2003-04-01
EP0702551B1 (de) 2002-09-25
DE69431433T2 (de) 2003-12-04
NO954437L (no) 1995-11-06
WO1994026249A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
DE69431433D1 (de) Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
ATE418986T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten
ZA918044B (en) Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines of piperazines,and compositions and methods of use thereof
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EP0709375A3 (de) Therapeutisch wirksame Heterocyclen
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
IE790756L (en) Cerebral therapeutic agent
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
EP0709376A3 (de) Therapeutisch wirksame Verbindungen
IL94990A0 (en) Pharmaceutical compositions for the prophylaxis and/or treatment of prostatic diseases
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
GB9523526D0 (en) Therapeutic compounds
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
YU6196A (sh) Transdermalna flasterska formulacija
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
TR200103144T2 (tr) Yeni bileşikler
IE780217L (en) 1,3,5-triazine-2,6-dione derivatives
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DK0986390T3 (da) Farmaceutiske præparater med cinchosin-dihydrochlorid
MX9602559A (es) Nuevos derivados de piperidina con actividad antagonista del paf.
CA2180660A1 (en) Novel piperidine derivatives with paf antagonist activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee